Thomas Spitznagel - 12 Feb 2026 Form 4 Insider Report for MACROGENICS INC (MGNX)

Reporting relationship: Sr VP, Technical Ops
Issuer ticker: MGNX
Reported as of: 12 Feb 2026
Net transaction value: -$9,439
SEC form: 4
Accepted by SEC: 17 Feb 2026, 18:24:23 UTC
Prior SEC filing: 10 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Beth A. Smith, Attorney-in-fact

Key filing fact

Thomas Spitznagel filed Form 4 for MACROGENICS INC (MGNX) on 17 Feb 2026.

Key facts

This page summarizes Thomas Spitznagel's Form 4 filing for MACROGENICS INC (MGNX).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 17 Feb 2026, 18:24.

Change

Previous filing in this sequence was filed on 10 Feb 2026.
Current net transaction value: -$9,439.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001675464 Primary reporting owner

Spitznagel Thomas

Relationship: Sr VP, Technical Ops
Address: 9704 MEDICAL CENTER DRIVE, ROCKVILLE
Signature: /s/ Beth A. Smith, Attorney-in-fact
Signature date: 17 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MGNX transaction

Common Stock

Options Exercise

Transaction value
Shares: +13,332
Change %: +43%
Price
Shares after: 44,063
Date: 15 Feb 2026
Ownership: Direct
Footnotes: F1

MGNX transaction

Common Stock

Tax liability

Transaction value: $9,439
Shares: -5,520
Change %: -13%
Price: $1.71
Shares after: 38,543
Date: 15 Feb 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MGNX transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -13,332
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 15 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,332
Exercise price
Footnotes: F1

MGNX transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +25,000
Change %
Price: $0.000000
Shares after: 25,000
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price
Footnotes: F2

MGNX transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +150,000
Change %
Price: $0.000000
Shares after: 150,000
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $1.71
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On February 15, 2023, the reporting person was granted 40,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis.

Footnote F2

Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.

Footnote F3

12.5% of the shares underlying the grant became exercisable one year after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.